Deborah E. Farr, MD
Associate Professor
UT Southwestern Medical Center
Dallas, Texas, United States
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
As shown in Table 1, ten women (median age 40, range 35-63 years) underwent SPrNSM with immediate tissue expander reconstruction. The most common surgical indication was risk-reducing surgery due to high-risk mutation (6 patients). Breast cup size ranged from A-D cup (median B), with median BMI of 24 (range, 22.1-27.8). Median operative time was 277 minutes (range 219-351) with no conversion to open procedure. In the four patients with breast cancer all final operative margins were negative. There were no intra-operative or 30-day adverse events. Nipple sensation was preserved in 18/20 breasts at 30 days.
Conclusions:
This first in human prospective study of SPrNSM with immediate tissue expander reconstruction demonstrates feasibility and safety in the initial patient experience. This encouraging early experience supports need for larger studies with longer measured oncologic outcomes.